Hologic CEO MacMillan on leading a turnaround and the importance of women’s health in medtech

Hologic CEO Stephen MacMillan

Stephen MacMillan joined a struggling Hologic (NSDQ:HOLX) as CEO in December 2013, and within one day, he had already made his first major move in restructuring the company’s executive leadership team.

MacMillan spoke in a keynote presentation at Device Talks Boston yesterday about his entry into the women’s healthcare market with Hologic, how his turn-around of the company included removing executives at the firm and the importance of women’s health and comfort in medtech.

In considering the overall health of a team, MacMillan said that removing the bad players is as important, if not more, than adding positive talent.

During his first 14 months in the corner office, MacMillan said that he removed 24 of the 25 execs that were on board when he joined. The one executive he didn’t remove, Karleen Oberton, was promoted to chief financial officer this August, MacMillan said.

Get the full story on our sister site MassDevice.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW